ISOSORBIDE MONONITRATE

ISOSORBIDE MONONITRATe
(eye-soe-sor'bide)
Ismo, Imdur, Monoket
Classifications: nitrate vasodilator;
Therapeutic: vasodilator
; nitrate
Prototype: Nitroglycerin
Pregnancy Category: C

Availability

10 mg, 20 mg tablets; 30 mg, 60 mg, 120 mg sustained release tablets

Action

Isosorbide mononitrate is a long-acting metabolite of the coronary vasodilator isosorbide dinitrate. It decreases preload as measured by pulmonary capillary wedge pressure (PCWP), and left ventricular end volume and diastolic pressure (LVEDV), with a consequent reduction in myocardial oxygen consumption.

Therapeutic Effect

It is equally or more effective than isosorbide dinitrate in the treatment of chronic, stable angina. It is a potent vasodilator with antianginal and antiischemic effects.

Uses

Prevention of angina. Not indicated for acute attacks.

Contraindications

Hypersensitivity to nitrates; severe anemia; closed-angle glaucoma; recent MI; postural hypotension, head trauma, cerebral hemorrhage (increases intracranial pressure); pregnancy (category C). Extended form should not be used in patients with GI disease.

Cautious Use

Older adults, hypotension; lactation.

Route & Dosage

Prevention of Angina
Adult: PO Regular release (ISMO, Monoket) 20 mg b.i.d. 7 h apart; Sustained release (Imdur) 30–60 mg every morning, may increase up to 120 mg once daily after several days if needed (max: dose 240 mg)

Administration

Oral
  • Give first dose in morning on arising and second dose 7 h later with twice daily dosing regimen. Give in morning on arising with once daily dosing.
  • Store sustained release tablets in a tight container.

Adverse Effects (≥1%)

CNS: Headache, agitation, anxiety, confusion, loss of coordination, hypoesthesia, hypokinesia, insomnia or somnolence, nervousness, migraine headache, paresthesia, vertigo, ptosis, tremor. CV: Aggravation of angina, abnormal heart sounds, murmurs, MI, transient hypotension, palpitations. Hematologic: Hypochromic anemia, purpura, thrombocytopenia, methemoglobinemia (high doses). GI: Nausea, vomiting, dry mouth, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, tenesmus, gastric ulcer, hemorrhoids, gastritis, glossitis. Metabolic: Hyperuricemia, hypokalemia. GU: Renal calculus, UTI, atrophic vaginitis, dysuria, polyuria, urinary frequency, decreased libido, impotence. Respiratory: Bronchitis, pneumonia, upper respiratory tract infection, nasal congestion, bronchospasm, coughing, dyspnea, rales, rhinitis. Skin: Rash, pruritus, hot flashes, acne, abnormal texture. Special Senses: Diplopia, blurred vision, photophobia, conjunctivitis.

Interactions

Drug: Alcohol may cause severe hypotension and cardiovascular collapse. Aspirin may increase nitrate serum levels. calcium channel blockers may cause orthostatic hypotension.

Pharmacokinetics

Absorption: Completely and rapidly absorbed from GI tract; 93% reaches systemic circulation. Onset: 1 h. Peak: Regular release 30–60 min; sustained release 3–4 h. Duration: Regular release 5–12 h; sustained release 12 h. Metabolism: In liver by denitration and conjugation to inactive metabolites. Elimination: Primarily by kidneys. Half-Life: 4–5 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor cardiac status, frequency and severity of angina, and BP.
  • Assess for and report possible S&S of toxicity, including orthostatic hypotension, syncope, dizziness, palpitations, light-headedness, severe headache, blurred vision, and difficulty breathing.
  • Lab tests: Monitor serum electrolytes periodically.

Patient & Family Education

  • Do not crush or chew sustained release tablets. May break tablets in two and take with adequate fluid (4–8 oz).
  • Do not withdraw drug abruptly; doing so may precipitate acute angina.
  • Maintain correct dosing interval with twice daily dosing.
  • Note: Geriatric patients are more susceptible to the possibility of developing postural hypotension.
  • Avoid alcohol ingestion and aspirin unless specifically permitted by physician.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(114)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 04/10/2025 (0.04)
×
Wait 20 seconds...!!!